Request availability and a quotation for your required quantity and destination.
| Product | Liraglutide 6 mg/mL - Saxenda Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Liraglutide
Listed strength: 6 mg/mL
Form: Subcutaneous injection pen
Class: GLP-1 receptor agonist
Supply: Prescription and destination-country regulations apply
Saxenda is a daily liraglutide injection for chronic weight management in patients meeting applicable eligibility criteria. The pen concentration of 6 mg/mL is not the administered daily dose; titration is directed by the prescriber. Product-specific indications and age limits differ internationally; verify the leaflet and the exact pen presentation before use.
Saxenda is intended as an adjunct to dietary and physical-activity measures for eligible patients needing chronic weight management. It is not an insulin product or an automatic substitute for another weight-management medicine.
Liraglutide activates GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon release and gastric emptying. Appetite effects can occur. This does not mean every person will experience the same glycaemic or weight response.
This liraglutide pen is generally injected once daily. Only follow the dose schedule and injection instructions provided by the prescriber and manufacturer. Subcutaneous sites include abdomen, thigh or upper arm depending on the product leaflet. Do not share pens, even if needles are changed. Do not alter the strength, reuse needles or combine GLP-1 medicines without professional guidance. Discuss storage and temperature-control requirements before international supply.
GLP-1 treatments carry clinically significant warnings. U.S. labeling includes a boxed thyroid C-cell tumor warning and contraindicates use with personal or family history of medullary thyroid carcinoma or MEN2. A previous serious allergic reaction to the active ingredient is also a contraindication. Discuss pregnancy, planned surgery requiring anaesthesia or deep sedation, pancreas or gallbladder disease, kidney problems, severe gastrointestinal effects and all concurrent medicines with the clinician.
Potential adverse effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Dehydration can contribute to kidney injury; hypoglycaemia may be more likely with insulin or sulfonylureas. Seek prompt medical care for persistent severe abdominal pain or allergic symptoms.
Explore Victoza Pen and Saxenda Pen. They contain liraglutide but have different indications and dose schedules. Read the existing Cureiva Related Cureiva readingsemaglutide product comparison for context. Links are educational, not substitution advice.
Review the Saxenda official prescribing information and the leaflet supplied with the actual product. Local indications may differ.
Yes. Appropriate medical assessment, documentation and local prescribing regulations apply.
No. 6 mg/mL is the concentration in the liraglutide solution. Actual daily doses are set by a clinician.
Do not switch or combine products without clinical guidance because dosing, indications and risk profiles differ.
Manufacturer storage instructions may require refrigeration before first use and specific temperature limits afterward. Check the exact pack and shipping feasibility.
No. Availability depends on prescribing requirements, product authenticity checks, transport suitability and destination-country rules.
Saxenda is generally administered once daily as a subcutaneous injection. Follow your prescriber’s titration plan and the instructions for your specific pen.
Both contain liraglutide, but their approved indications and dosing schedules differ. They should not be combined or substituted without medical supervision.
Consult the pack leaflet. U.S. labeling advises contacting your healthcare provider about restarting if more than three days have passed since the last dose; do not simply resume the prior dose.
A clinician should review tolerability, response and whether treatment should continue using the product-specific criteria and local guidance.
Weight-loss treatment with Saxenda is not recommended during pregnancy. Discuss pregnancy or pregnancy plans with your clinician promptly.
Cureiva Healthcare handles business and individual-patient product enquiries where permitted. This information is educational, is not a personal medical recommendation and does not claim individual physician review.
Reference check: October 2026.